Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.81 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.81 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.81 |
| ▸ | MPL | P40238 | 13/20 | 0.72 |
| ▸ | CTRC | Q99895 | 2/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | PTPRA | P18433 | 1/20 | 0.55 |
| ▸ | PTPRB | P23467 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727468 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL6003958 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL1139885 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL29407321 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL184951 | 0.99 | CYP1A2 (0.80) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL29357895 | 0.99 | CYP1A2 (0.80) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL184949 | 0.99 | CYP1A2 (0.80) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL30808001 | 0.99 | CYP1A2 (0.80) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL184950 | 0.90 | CYP1A2 (0.67) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 | |
| SCHEMBL29358115 | 0.90 | CYP1A2 (0.67) | CYP1A2CYP2C9TSHRCYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670387-B1 | Thrombocytopenia; hydroxy-1-azo-naphthalene derivatives; 3-hydroxy-4-((2-hydroxy-1-naphthalenyl)azo-)-1-naphthalenesul fonic acid; promoters of thrombopoiesis and megakaryocytopoi esis; enhancing platelet production; agonizing TPO receptor | SMITHKLINE BEECHAM CORPORATION | 2003-12-30 | — | — | US | claimed |
| EP-1156804-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| EP-1156804-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2000035446-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-06-21 | — | — | US | disclosed |
| US-20210060523-A1 | MODIFIED PROTEIN ADSORBENTS FOR CONTAMINANT REMOVAL | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2021-03-04 | — | — | US | disclosed |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-12-17 | — | — | US | disclosed |
| US-20190002569-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | UNIVERSITÉ PARIS CITÉ (FR) | 2019-01-03 | — | — | US | disclosed |
| EP-2424491-B1 | FILM FORMER IN HAIR COLOURS | HENKEL AG & CO KGAA (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20170051062-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-02-23 | — | — | US | disclosed |
| US-20170051062-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-02-23 | — | — | US | disclosed |
| US-9504637-B2 | Coloring agents and methods of use thereof | LIVING PROOF, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-7018426-B2 | Oxidation dye | WELLA AG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6670387-B1 | Thrombocytopenia; hydroxy-1-azo-naphthalene derivatives; 3-hydroxy-4-((2-hydroxy-1-naphthalenyl)azo-)-1-naphthalenesul fonic acid; promoters of thrombopoiesis and megakaryocytopoi esis; enhancing platelet production; agonizing TPO receptor | SMITHKLINE BEECHAM CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-20030159222-A1 | Oxidation dye | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2003-08-28 | — | — | US | disclosed |
| US-20020189031-A1 | Use of salts for improving the absorption qualities of anionic direct dyes | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | US | disclosed |
| EP-0799260-B1 | PROCESS FOR PREPARING DYED MELAMINE-FORMALDEHYDE CONDENSATION PRODUCTS | BASF AG (DE) | 1999-05-06 | — | — | EP | disclosed |
| US-5837013-A | Preparation of colored melamine-formaldehyde condensation products | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-17 | — | — | US | disclosed |
| US-5624466-A | DYEING FIBERS, KNITS, NONWOVENS WITH AZO, ANTHRAQUINONE, COUMARIN, METHINE, QUINOPHTHALONE OR NITRO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| EP-0702107-A2 | Process for dyeing melamine-formaldehyde condensation products | BASF Aktiengesellschaft (DE) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051062-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | NR0B1, NRP1, NR0B2 | CYP1A2 4539/4885CYP2C9 4841/4885TSHR 135/4885 |
| US-20030159222-A1 | Oxidation dye | KRT18, NOX4, VIM | CYP1A2 384/4885CYP2C9 1339/4885TSHR 4742/4885 |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | PER2, CRY1, CRY2 | CYP1A2 642/4885CYP2C9 2388/4885TSHR 4837/4885 |
| US-20190002569-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | NR0B1, NRP1, NR0B2 | CYP1A2 4539/4885CYP2C9 4841/4885TSHR 135/4885 |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | PER2, CRY1, CRY2 | CYP1A2 642/4885CYP2C9 2388/4885TSHR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.